THERAPY DOSSIER · th-1f5c55dd432e

Aspirin-triggered resolvin D1 (AT-RvD1)

Drug · No confident ChEMBL match; specialized pro-resolving lipid mediator (resolvin D1 epimer)

Evidence & regulatory context

Mechanism: No confident ChEMBL match; specialized pro-resolving lipid mediator (resolvin D1 epimer)
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: AT-RvD1
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25647402 ↗2015Reported benefit

Enhanced Resolution of Hyperoxic Acute Lung Injury as a result of Aspirin Triggered Resolvin D1 Treatment.

MouseOtherC57BL/6100 ngAfter the 48 h hyperoxia exposure, during 24 h of normoxic recovery

Model: Hyperoxic acute lung injury, exposure to at least 95% oxygen for 48 h

AT-RvD1 reduced oxidative stress, increased glutathione, decreased tissue inflammation, lung wet to dry ratio and bronchoalveolar lavage protein, and lowered apoptotic and NF-kappaB signalling after prolonged hyperoxia.

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…